Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer

European Radiology

Volumn 21, Issue 3, 2011, Pages 616-626

  Franiel, Tobias ^a   Hamm, Bernd ^b   Hricak, Hedvig ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Blood flow; DCE MRI; Permeability; Pharmacokinetic parameters; Prostate

Indexed keywords

BEVACIZUMAB; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; THALIDOMIDE;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CONTRAST ENHANCEMENT; CONTRAST RADIOGRAPHY; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOLOGICAL PARAMETERS; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; COMPUTER SIMULATION; CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MODELS, BIOLOGICAL; PERFUSION IMAGING; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 79751525792     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-010-2037-7     Document Type: Article

References (100)

1. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 10.3322/caac.20006 19474385
2. H Hricak PL Choyke SC Eberhardt SA Leibel PT Scardino 2007 Imaging prostate cancer: a multidisciplinary perspective Radiology 243 28 53 10.1148/radiol.2431030580 17392247 (Pubitemid 46579693)
3. ML Schiebler JE Tomaszewski M Bezzi, et al. 1989 Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings Radiology 172 131 137 1:STN:280:DyaL1M3psleksA%3D%3D 2472644 (Pubitemid 19192495)
4. D Beyersdorff M Taupitz B Winkelmann, et al. 2002 Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging Radiology 224 701 706 10.1148/radiol.2243011553 12202702 (Pubitemid 34919801)
5. E Sala SC Eberhardt O Akin, et al. 2006 Endorectal MR imaging before salvage prostatectomy: tumor localization and staging Radiology 238 176 183 10.1148/radiol.2381052345 16373766 (Pubitemid 43010594)
6. FV Coakley HS Teh A Qayyum, et al. 2004 Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience Radiology 233 441 448 10.1148/radiol.2332032086 15375223 (Pubitemid 39423803)
7. YJ Choi JK Kim N Kim KW Kim EK Choi KS Cho 2007 Functional MR imaging of prostate cancer Radiographics 27 63 75 10.1148/rg.271065078 17234999 discussion 75-67
8. SA Mirowitz JJ Brown JP Heiken 1993 Evaluation of the prostate and prostatic carcinoma with gadolinium-enhanced endorectal coil MR imaging Radiology 186 153 157 1:STN:280:DyaK3s7gtFOrtQ%3D%3D 8416557 (Pubitemid 23005481)
9. G Brown DA Macvicar V Ayton JE Husband 1995 The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma Clin Radiol 50 601 606 1:STN:280:DyaK28%2FktFWnug%3D%3D 10.1016/S0009-9260(05)83288-X 7554733
10. MR Engelbrecht HJ Huisman RJ Laheij, et al. 2003 Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging Radiology 229 248 254 10.1148/radiol. 2291020200 12944607 (Pubitemid 37152132)
11. B Nicholson G Schaefer D Theodorescu 2001 Angiogenesis in prostate cancer: biology and therapeutic opportunities Cancer Metastasis Rev 20 297 319 1:CAS:528:DC%2BD38XkvVWqs7w%3D 10.1023/A:1015543713485 12085968 (Pubitemid 34595273)
12. J Folkman P Cole S Zimmerman 1996 Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment Ann Surg 164 491 502 10.1097/00000658-196609000-00012
13. MW Dewhirst CY Tso R Oliver CS Gustafson TW Secomb JF Gross 1989 Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature Int J Radiat Oncol Biol Phys 17 91 99 1:STN:280: DyaL1MzgvVWltg%3D%3D 2745213 (Pubitemid 19173243)
14. J Pallares F Rojo J Iriarte J Morote LI Armadans I de Torres 2006 Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues Histol Histopathol 21 857 865 1:CAS:528:DC%2BD28XhtF2gsLfI 16691538 (Pubitemid 44082728)
15. SA Bigler RE Deering MK Brawer 1993 Comparison of microscopic vascularity in benign and malignant prostate tissue Hum Pathol 24 220 226 1:STN:280:DyaK3s7mt1KgsA%3D%3D 10.1016/0046-8177(93)90304-Y 8432518 (Pubitemid 23066603)
16. JA Siegal E Yu MK Brawer 1995 Topography of neovascularity in human prostate carcinoma Cancer 75 2545 2551 1:STN:280:DyaK2M3lsVCntg%3D%3D 10.1002/1097-0142(19950515)75:10<2545::AID-CNCR2820751022>3.0.CO;2-X 7537624
17. N Weidner PR Carroll J Flax W Blumenfeld J Folkman 1993 Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma Am J Pathol 143 401 409 1:STN:280:DyaK3szktlWqtQ%3D%3D 7688183 (Pubitemid 24058195)
18. MA Silberman AW Partin RW Veltri JI Epstein 1997 Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate Cancer 79 772 779 1:STN:280:DyaK2s7nslWlsQ%3D%3D 10.1002/(SICI)1097-0142(19970215)79:4<772:: AID-CNCR14>3.0.CO;2-X 9024715 (Pubitemid 27076343)
19. MA Rubin M Buyyounouski E Bagiella, et al. 1999 Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome Urology 53 542 547 1:STN:280:DyaK1M7psVSntw%3D%3D 10.1016/S0090-4295(98)00561-5 10096381 (Pubitemid 29136199)
20. A Erbersdobler H Isbarn K Dix, et al. 2010 Prognostic value of microvessel density in prostate cancer: a tissue microarray study World J Urol 28 687 692 10.1007/s00345-009-0471-4 19714336
21. J Concato D Jain WW Li HA Risch EM Uchio CK Wells 2007 Molecular markers and mortality in prostate cancer BJU Int 100 1259 1263 10.1111/j.1464-410X.2007. 07136.x 17850375 (Pubitemid 350043905)
22. LA Mucci A Powolny E Giovannucci, et al. 2009 Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study J Clin Oncol 27 5627 5633 10.1200/JCO.2008.20.8876 19858401
23. HJ Huisman MR Engelbrecht JO Barentsz 2001 Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate J Magn Reson Imaging 13 607 614 1:STN:280:DC%2BD3M7os1Cjsg%3D%3D 10.1002/jmri.1085 11276106 (Pubitemid 32231516)
24. U Hoffmann G Brix MV Knopp T Hess WJ Lorenz 1995 Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography Magn Reson Med 33 506 514 1:STN:280:DyaK2M3psFGmtg%3D%3D 10.1002/mrm.1910330408 7776881
25. D Prochnow D Beyersdorff C Warmuth M Taupitz O Gemeinhardt L Lüdemann 2005 Implementation of a rapid inversion-prepared dual-contrast gradient echo sequence for quantitative dynamic contrast-enhanced magnetic resonance imaging of the human prostate Magn Reson Imaging 23 983 990 10.1016/j.mri.2005.09.010 16376181 (Pubitemid 41821038)
26. F Taillieu LJ Salomon N Siauve, et al. 2006 Placental perfusion and permeability: simultaneous assessment with dual-echo contrast-enhanced MR imaging in mice Radiology 241 737 745 10.1148/radiol.2413051168 17065560 (Pubitemid 46190539)
27. C de Bazelaire NM Rofsky G Duhamel, et al. 2006 Combined T2* and T1 measurements for improved perfusion and permeability studies in high field using dynamic contrast enhancement Eur Radiol 16 2083 2091 10.1007/s00330-006- 0198-1 16583215 (Pubitemid 44193193)
28. S Walker-Samuel MO Leach DJ Collins 2007 Reference tissue quantification of DCE-MRI data without a contrast agent calibration Phys Med Biol 52 589 601 10.1088/0031-9155/52/3/004 17228107 (Pubitemid 46646433)
29. J Pintaske P Martirosian H Graf, et al. 2006 Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla Invest Radiol 41 213 221 10.1097/01.rli.0000197668.44926.f7 16481903 (Pubitemid 44406181)
30. HL Cheng GA Wright 2006 Rapid high-resolution T(1) mapping by variable flip angles: accurate and precise measurements in the presence of radiofrequency field inhomogeneity Magn Reson Med 55 566 574 10.1002/mrm.20791 16450365
31. RE Port MV Knopp G Brix 2001 Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors Magn Reson Med 45 1030 1038 1:CAS:528:DC%2BD3MXktlyhtbw%3D 10.1002/mrm.1137 11378881 (Pubitemid 32488330)
32. M Rijpkema JH Kaanders FB Joosten AJ van der Kogel A Heerschap 2001 Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors J Magn Reson Imaging 14 457 463 1:STN:280:DC%2BD3MrkvFOjsw%3D%3D 10.1002/jmri.1207 11599071 (Pubitemid 32906564)
33. PS Tofts G Brix DL Buckley, et al. 1999 Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols J Magn Reson Imaging 10 223 232 1:STN:280:DyaK1Mvjsl2jtw%3D%3D 10.1002/(SICI)1522-2586(199909)10:3<223::AID- JMRI2>3.0.CO;2-S 10508281 (Pubitemid 29463104)
34. J Feldschuh S Katz 2007 The importance of correct norms in blood volume measurement Am J Med Sci 334 41 46 10.1097/MAJ.0b013e318063c707 17630591 (Pubitemid 47067444)
35. HJ Weinmann M Laniado W Mutzel 1984 Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers Physiol Chem Phys Med NMR 16 167 172 1:CAS:528:DyaL2cXmt1Kit7c%3D 6505043
36. T Fritz-Hansen E Rostrup HB Larsson L Sondergaard P Ring O Henriksen 1996 Measurement of the arterial concentration of Gd-DTPA using MRI: a step toward quantitative perfusion imaging Magn Reson Med 36 225 231 1:CAS:528: DyaK28Xlt1Cltbw%3D 10.1002/mrm.1910360209 8843376 (Pubitemid 26271742)
37. GJ Parker C Roberts A Macdonald, et al. 2006 Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI Magn Reson Med 56 993 1000 10.1002/mrm.21066 17036301 (Pubitemid 44691341)
38. RE Port MV Knopp U Hoffmann S Milker-Zabel G Brix 1999 Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging J Magn Reson Imaging 10 233 241 1:STN:280:DyaK1Mvjsl2jtA%3D%3D 10.1002/(SICI)1522-2586(199909)10:3<233::AID- JMRI3>3.0.CO;2-M 10508282 (Pubitemid 29463105)
39. G Brix W Semmler R Port LR Schad G Layer WJ Lorenz 1991 Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging J Comput Assist Tomogr 15 621 628 1:STN:280:DyaK3M3os1Gjtg%3D%3D 10.1097/00004728-199107000-00018 2061479
40. G Brix W Schreiber U Hoffmann F Guckel H Hawighorst MV Knopp 1997 Methodological approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography Radiologe 37 470 480 1:STN:280:DyaK2svhvVKntA%3D%3D 10.1007/s001170050241 9340677 (Pubitemid 27315875)
41. PS Tofts AG Kermode 1991 Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts Magn Reson Med 17 357 367 1:STN:280:DyaK3M3oslGiug%3D%3D 10.1002/mrm.1910170208 2062210
42. PS Tofts B Berkowitz MD Schnall 1995 Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model Magn Reson Med 33 564 568 1:STN:280:DyaK2M3psFGlsA%3D%3D 10.1002/mrm.1910330416 7776889
43. HF Dvorak LF Brown M Detmar AM Dvorak 1995 Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis Am J Pathol 146 1029 1039 1:CAS:528:DyaK2MXmt1Kkt7g%3D 7538264
44. LE Gerlowski RK Jain 1986 Microvascular permeability of normal and neoplastic tissues Microvasc Res 31 288 305 1:STN:280:DyaL283jtVWltg%3D%3D 10.1016/0026-2862(86)90018-X 2423854 (Pubitemid 16076428)
45. KS St. Lawrence TY Lee 1998 An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: II. experimental validation J Cereb Blood Flow Metab 18 1378 1385 1:STN:280:DyaK1M%2FmsFCjsA%3D%3D 10.1097/00004647-199812000-00012 9850150 (Pubitemid 28559685)
46. LE Kershaw DL Buckley 2006 Precision in measurements of perfusion and microvascular permeability with T1-weighted dynamic contrast-enhanced MRI Magn Reson Med 56 986 992 10.1002/mrm.21040 16986107 (Pubitemid 44691340)
47. L Lüdemann D Prochnow T Rohlfing, et al. 2009 Simultaneous quantification of perfusion and permeability in the prostate using dynamic contrast-enhanced magnetic resonance imaging with an inversion-prepared dual-contrast sequence Ann Biomed Eng 37 749 762 10.1007/s10439-009-9645-x 19169821
48. JL Stephenson 1948 Theory of the measurement of blood flow by the dilution of an indicator Bull Math Biophys 10 117 121 1:STN:280: DyaH1c%2FivVWhsg%3D%3D 10.1007/BF02477486 18884373
49. American Urological Association (2007) Guideline for management of clinically localized prostate cancer: 2007 update. In. http://www.auanet.org/ content/guidelines-and-quality-care/clinical-guidelines/main-reports/proscan07/ content.pdf, 2007
50. DW Keetch WJ Catalona DS Smith 1994 Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values J Urol 151 1571 1574 1:STN:280:DyaK2c3ks1Orug%3D%3D 7514690 (Pubitemid 24151304)
51. KA Roehl JA Antenor WJ Catalona 2002 Serial biopsy results in prostate cancer screening study J Urol 167 2435 2439 10.1016/S0022-5347(05)64999-3 11992052 (Pubitemid 34533140)
52. DL Langer TH van der Kwast AJ Evans J Trachtenberg BC Wilson MA Haider 2009 Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI J Magn Reson Imaging 30 327 334 10.1002/jmri.21824 19629981
53. A Tanimoto J Nakashima H Kohno H Shinmoto S Kuribayashi 2007 Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging J Magn Reson Imaging 25 146 152 10.1002/jmri.20793 17139633 (Pubitemid 46095209)
54. Franiel T, Lüdemann L, Rudolph B, et al (2009) Prostate MR imaging: tissue characterization with pharmacokinetic volume and blood flow parameters and correlation with histologic parameters. Radiology 252:101-108
55. AB Cheikh N Girouin M Colombel, et al. 2009 Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy Eur Radiol 19 770 778 10.1007/s00330-008-1190-8 18925403
56. Hambrock T, Futterer JJ, Huisman HJ et al (2008) Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol 43:686-694
57. S Xu J Kruecker B Turkbey, et al. 2008 Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies Comput Aided Surg 13 255 264 18821344
58. H Hricak L Wang DC Wei, et al. 2004 The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy Cancer 100 2655 2663 10.1002/cncr.20319 15197809 (Pubitemid 38715772)
59. Jackson AS, Reinsberg SA, Sohaib SA, et al (2009) Dynamic contrast-enhanced MRI for prostate cancer localization. Br J Radiol 82:148-156
60. Futterer JJ, Heijmink SW, Scheenen TW et al (2006) Prostate Cancer Localization with Dynamic Contrast-enhanced MR Imaging and Proton MR Spectroscopic Imaging. Radiology 241:449-458 (Pubitemid 44632891)
61. Ocak I, Bernardo M, Metzger G et al (2007) Dynamic contrast-enhanced MRI of prostate cancer at 3T: a study of pharmacokinetic parameters. AJR Am J Roentgenol 189:849
62. D Beyersdorff K Taymoorian T Knosel, et al. 2005 MRI of prostate cancer at 1.5 and 3.0T: comparison of image quality in tumor detection and staging AJR Am J Roentgenol 185 1214 1220 10.2214/AJR.04.1584 16247137
63. SW Heijmink JJ Futterer T Hambrock, et al. 2007 Prostate cancer: body-array versus endorectal coil MR imaging at 3T-comparison of image quality, localization, and staging performance Radiology 244 184 195 10.1148/radiol. 2441060425 17495178 (Pubitemid 46981973)
64. BN Bloch E Furman-Haran TH Helbich, et al. 2007 Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging-initial results Radiology 245 176 185 10.1148/radiol.2451061502 17717328 (Pubitemid 47417801)
65. AV D'Amico R Whittington SB Malkowicz, et al. 2002 Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era Cancer 95 281 286 10.1002/cncr.10657 12124827 (Pubitemid 34787593)
66. LL Kestin FA Vicini EL Ziaja JS Stromberg RC Frazier AA Martinez 1999 Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy Cancer 86 1557 1566 1:STN:280:DC%2BD3c%2FhtVSjtQ%3D%3D 10.1002/(SICI)1097-0142(19991015)86:8<1557::AID-CNCR24>3.0.CO;2-2 10526285 (Pubitemid 29489791)
67. CR Pound MK Brawer AW Partin 2001 Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer Rev Urol 3 72 84 1:STN:280: DC%2BD28rmtVOmtg%3D%3D 16985694
68. DM Nudell AE Wefer H Hricak PR Carroll 2000 Imaging for recurrent prostate cancer Radiol Clin North Am 38 213 229 1:STN:280:DC%2BD3c7ivVSmuw%3D%3D 10.1016/S0033-8389(05)70157-3 10664674 (Pubitemid 30059013)
69. T Sella LH Schwartz PW Swindle, et al. 2004 Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging Radiology 231 379 385 10.1148/radiol.2312030011 15064390 (Pubitemid 38552892)
70. S Cirillo M Petracchini L Scotti, et al. 2009 Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging Eur Radiol 19 761 769 10.1007/s00330-008-1174-8 18825386
71. MA Haider P Chung J Sweet, et al. 2008 Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy Int J Radiat Oncol Biol Phys 70 425 430 10.1016/j.ijrobp.2007. 06.029 17881141
72. O Rouviere O Valette S Grivolat, et al. 2004 Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor-correlation with biopsy findings Urology 63 922 927 10.1016/j.urology.2003.12.017 15134982 (Pubitemid 38596680)
73. Yakar D, Hambrock T, Huisman H et al (2010) Feasibility of 3T dynamic contrast-enhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy. Invest Radiol 45:121-125
74. Moman MR, van den Berg CA, Boeken Kruger AE et al (2010) Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences. Int J Radiat Oncol Biol Phys 76:741-746
75. E Casciani E Polettini E Carmenini, et al. 2008 Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy AJR Am J Roentgenol 190 1187 1192 10.2214/AJR.07.3032 18430830 (Pubitemid 351684918)
76. KR Zand C Reinhold MA Haider A Nakai L Rohoman S Maheshwari 2007 Artifacts and pitfalls in MR imaging of the pelvis J Magn Reson Imaging 26 480 497 10.1002/jmri.20996 17623875 (Pubitemid 350194568)
77. O Rouviere N Girouin L Glas, et al. 2010 Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI Eur Radiol 20 48 55 10.1007/s00330-009-1520-5 19690866
78. FH Schroder J Hugosson MJ Roobol, et al. 2009 Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 1320 1328 10.1056/NEJMoa0810084 19297566
79. R Choo L Klotz C Danjoux, et al. 2002 Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression J Urol 167 1664 1669 10.1016/S0022-5347(05)65174-9 11912384 (Pubitemid 34240696)
80. MA Dall'Era MR Cooperberg JM Chan, et al. 2008 Active surveillance for early-stage prostate cancer: review of the current literature Cancer 112 1650 1659 10.1002/cncr.23373 18306379 (Pubitemid 351536825)
81. FV Coakley I Chen A Qayyum, et al. 2007 Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging BJU Int 99 41 45 1:CAS:528:DC%2BD2sXhtlSjsLs%3D 10.1111/j.1464-410X.2006.06515.x 17227490 (Pubitemid 44915616)
82. GS Kulkarni G Lockwood A Evans, et al. 2007 Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy Cancer 109 2432 2438 10.1002/cncr.22712 17497649 (Pubitemid 46906461)
83. CK Poulos JK Daggy L Cheng 2004 Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens Cancer 101 527 532 10.1002/cncr.20415 15274065 (Pubitemid 38970603)
84. L Wang Y Mazaheri J Zhang NM Ishill K Kuroiwa H Hricak 2008 Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy Radiology 246 168 176 10.1148/radiol.2461070057 18024440 (Pubitemid 350305040)
85. Franiel T, Lüdemann L, Taupitz M, Rost J, Asbach P, Beyersdorff D (2009) Pharmacokinetic MRI of the prostate: parameters for differentiating low-grade and high-grade prostate cancer. Rofo 181:536-542
86. Schlemmer HP, Merkle J, Grobholz R et al (2004) Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 14:309-317 (Pubitemid 38181089)
87. Kiessling F, Lichy M, Grobholz R et al (2004) Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI. Eur Radiol 14:1793-1801 (Pubitemid 39386627)
88. M Roach 3rd 2003 Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: "love the one you're with" and "do the right thing" Int J Radiat Oncol Biol Phys 57 907 909 10.1016/S0360-3016(03)01619-5 14575819 (Pubitemid 37324106)
89. R Takamiya V Weinberg CD Young H Sandler P McLaughlin M Roach 3rd 2003 A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 56 1073 1078 10.1016/S0360- 3016(03)00206-2 12829144 (Pubitemid 36794040)
90. AL Hanlon WH Pinover EM Horwitz GE Hanks 2001 Patterns and fate of PSA bouncing following 3D-CRT Int J Radiat Oncol Biol Phys 50 845 849 1:STN:280:DC%2BD3Mznt1KmtA%3D%3D 10.1016/S0360-3016(01)01557-7 11429210 (Pubitemid 32594825)
91. W Cavanagh JC Blasko PD Grimm JE Sylvester 2000 Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer Semin Urol Oncol 18 160 165 1:STN:280: DC%2BD3cvotFequw%3D%3D 10875459 (Pubitemid 30395868)
92. B Pickett J Kurhanewicz F Coakley K Shinohara B Fein M Roach 3rd 2004 Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 60 1047 1055 10.1016/j.ijrobp.2004. 06.118 15519774 (Pubitemid 39440788)
93. Franiel T, Lüdemann L, Taupitz M, Bohmer D, Beyersdorff D (2009) MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: the feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Radiother Oncol 93:241-245
94. Padhani AR, MacVicar AD, Gapinski CJ et al (2001) Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology 218:365-374 (Pubitemid 32121045)
95. Jia G, Heverhagen JT, Henry H et al (2006) Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI. Magn Reson Imaging 24:721-725 (Pubitemid 43974887)
96. Maxwell RJ, Wilson J, Prise VE et al (2002) Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 15:89-98 (Pubitemid 34213398)
97. Franiel T, Lüdemann L, Rudolph B et al (2008) Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Invest Radiol 43:481-487
98. N Ferrara RS Kerbel 2005 Angiogenesis as a therapeutic target Nature 438 967 974 1:CAS:528:DC%2BD2MXhtlSksrnI 10.1038/nature04483 16355214 (Pubitemid 43093963)
99. PG Kluetz WD Figg WL Dahut 2010 Angiogenesis inhibitors in the treatment of prostate cancer Expert Opin Pharmacother 11 233 247 1:CAS:528: DC%2BC3cXhsVGrsrg%3D 10.1517/14656560903451716 20088745
100. J Tsao MS Hansen S Kozerke 2006 Accelerated parallel imaging by transform coding data compression with k-t SENSE Conf Proc IEEE Eng Med Biol Soc 1 372 10.1109/IEMBS.2006.259751 17946824 (Pubitemid 46519876)